Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 16/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131238 | 0.87 | CSF1R (0.43) | NR1H4CSF1R | |
| SCHEMBL15630537 | 0.80 | TRPM8 (0.51) | NR1H4TRPM8 | |
| SCHEMBL2129436 | 0.72 | CSF1R (0.43) | NR1H4CSF1R | |
| SCHEMBL27667297 | 0.70 | PTGER4 (0.47) | NR1H4TRPM8 | |
| SCHEMBL11564854 | 0.70 | TRPM8 (0.44) | NR1H4TRPM8EGFRCSF1R | |
| SCHEMBL11565561 | 0.70 | HCAR3 (0.66) | RXRARXRBRXRG | |
| SCHEMBL2129386 | 0.69 | LMNA (0.44) | NR1H4 | |
| SCHEMBL10766037 | 0.69 | MEN1 (0.58) | TRPM8RXRARXRBRXRG | |
| SCHEMBL10373059 | 0.68 | RXRA (0.58) | RXRARXRBRXRG | |
| SCHEMBL11564474 | 0.67 | HCAR3 (0.54) | TRPM8RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101511813-B | Heterocyclic FXR binding compounds | PHENEX PHARMACEUTICALS AG | 2012-12-12 | — | — | CN | disclosed |
| EP-2084147-B1 | HETEROCYCLIC FXR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2012-04-25 | — | — | EP | disclosed |
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | PHENEX PHARMACEUTICALS AG (DE) | 2010-07-22 | — | — | US | disclosed |
| CN-101511813-A | Heterocyclic FXR binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2009-08-19 | — | — | CN | disclosed |
| EP-2084147-A1 | HETEROCYCLIC FXR BINDING COMPOUNDS | Phenex Pharmaceuticals AG (DE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008025540-A1 | HETEROCYCLIC FXR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184809-A1 | Heterocyclic FXR Binding Compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TRPM8 456/4885RXRA 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.